| COVID-19 and sex differences: mechanisms and biomarkers T Haitao, JV Vermunt, J Abeykoon, R Ghamrawi, M Gunaratne, ... Mayo Clinic Proceedings 95 (10), 2189-2203, 2020 | 308 | 2020 |
| Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia J Paludo, JP Abeykoon, A Shreders, SM Ansell, S Kumar, S Ailawadhi, ... Annals of hematology 97, 1417-1425, 2018 | 86 | 2018 |
| Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis JP Abeykoon, S Zanwar, A Dispenzieri, MA Gertz, N Leung, T Kourelis, ... Leukemia 33 (2), 531-536, 2019 | 85 | 2019 |
| Progression risk stratification of asymptomatic Waldenström macroglobulinemia M Bustoros, R Sklavenitis-Pistofidis, P Kapoor, CJ Liu, E Kastritis, ... Journal of Clinical Oncology 37 (16), 1403, 2019 | 81 | 2019 |
| The promise of the gut microbiome as part of individualized treatment strategies DA Schupack, RAT Mars, DH Voelker, JP Abeykoon, PC Kashyap Nature reviews Gastroenterology & hepatology 19 (1), 7-25, 2022 | 77 | 2022 |
| MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia JP Abeykoon, J Paludo, RL King, SM Ansell, MA Gertz, BR LaPlant, ... American journal of hematology 93 (2), 187-194, 2018 | 67 | 2018 |
| Efficacy of daratumumab‐based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials A Lakshman, JP Abeykoon, SK Kumar, SV Rajkumar, D Dingli, FK Buadi, ... American journal of hematology 92 (11), 1146-1155, 2017 | 47 | 2017 |
| Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes JP Abeykoon, S Zanwar, SM Ansell, MA Gertz, S Kumar, M Manske, ... British journal of haematology 188 (3), 394-403, 2020 | 46 | 2020 |
| Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma X Wu, M Stenson, J Abeykoon, K Nowakowski, L Zhang, J Lawson, ... Blood, The Journal of the American Society of Hematology 134 (4), 363-373, 2019 | 44 | 2019 |
| Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia S Zanwar, JP Abeykoon, E Durot, R King, GE Perez Burbano, S Kumar, ... American journal of hematology 95 (3), 274-281, 2020 | 40 | 2020 |
| “Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience I Vaxman, J Abeykoon, A Dispenzieri, SK Kumar, F Buadi, MQ Lacy, ... Blood cancer journal 11 (12), 196, 2021 | 35 | 2021 |
| Primary systemic amyloidosis in patients with Waldenström macroglobulinemia S Zanwar, JP Abeykoon, SM Ansell, MA Gertz, A Dispenzieri, E Muchtar, ... Leukemia 33 (3), 790-794, 2019 | 35 | 2019 |
| Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment‐naïve patients with Waldenstrom macroglobulinemia J Paludo, JP Abeykoon, S Kumar, A Shreders, S Ailawadhi, MA Gertz, ... British journal of haematology 179 (1), 98-105, 2017 | 34 | 2017 |
| Drugs with anti-oxidant properties can interfere with cell viability measurements by assays that rely on the reducing property of viable cells N Shenoy, M Stenson, J Lawson, J Abeykoon, M Patnaik, X Wu, T Witzig Laboratory Investigation 97 (5), 494-497, 2017 | 34 | 2017 |
| Magnesium: The overlooked electrolyte in blood cancers? J Gile, G Ruan, J Abeykoon, MM McMahon, T Witzig Blood reviews 44, 100676, 2020 | 33 | 2020 |
| Efficacy of BRAF‐Inhibitor Therapy in BRAFV600E‐Mutated Adult Langerhans Cell Histiocytosis AZ Hazim, GJ Ruan, A Ravindran, JP Abeykoon, C Scheckel, R Vassallo, ... The Oncologist 25 (12), 1001-1004, 2020 | 30 | 2020 |
| Common adverse effects of novel therapies for multiple myeloma (MM) and their management strategies KB McCullough, MA Hobbs, JP Abeykoon, P Kapoor Current hematologic malignancy reports 13, 114-124, 2018 | 26 | 2018 |
| New developments in the management of Waldenström macroglobulinemia JP Abeykoon, U Yanamandra, P Kapoor Cancer Management and Research, 73-83, 2017 | 25 | 2017 |
| Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia JP Abeykoon, S Zanwar, SM Ansell, J Winters, MA Gertz, RL King, ... American journal of hematology 93 (11), 1384-1393, 2018 | 24 | 2018 |
| The effect of implementing gene expression classifier on outcomes of thyroid nodules with indeterminate cytology JP Abeykoon, L Mueller, F Dong, AV Chintakuntlawar, J Paludo, ... Hormones and Cancer 7, 272-278, 2016 | 23 | 2016 |
